Page 2 - Loncode Institute News Today

What type of brain tumor does this patient have? AI technology helps to determine this as early as during surgery, within 1.5 hours. This process normally takes a week.

A new study describes a method for faster and more precise diagnoses, which can help surgeons decide how aggressively to operate.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ... | May 10, 2023

Company developing targeted oncology therapies spun out of world-leading research at the Wellcome Sanger Institute, in collaboration with the Netherlands Cancer Institute Syncona and Cambridge

Company developing targeted oncology therapies spun out of world-leading research at the Wellcome Sanger Institute, in collaboration with the Netherlands Cancer Institute ... | April 4, 2023

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Company developing targeted oncology therapies spun out of world-leading research at the Wellcome Sanger Institute, in collaboration with the Netherlands Cancer Institute Syncona and Cambridge Innovation Capital invested Former Novartis SVP appointed as CEO to drive growth ambitions Mosaic Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ... | March 29, 2023

Gene test could guide use of cancer chemotherapy Test selects patients who would benefit from chemotherapy in advanced bowel cancer Can assess whether chemotherapy is likely to work – and spare those who are not going to benefit Test already used in NHS cancer care – and can become first t...

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts). Neogene will operate as a wholly owned subsidiary of AstraZeneca, with ...